Conversion Strategy for LI-RADS Category 5 Observations across Versions 2014, 2017, and 2018
Radiology · 01.05.2023 · 307 (4)
DOI: 10.1148/radiol.222971 ↗Kurz gefasst
Editorial in der Zeitschrift Radiology, erschienen am 01.05.2023. Verfasst von Stacy M Goins und 8 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Can…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (R.G.A.); The Ottawa Hospital Research Insitute, Clinical Epidemio…
ORCID-Profile: Stacy M Goins, Eric Lam, Christian B van der Pol, Jean-Paul Salameh, Matthew D F McInnes, Mustafa R Bashir
Zitieren
APA
Goins, S. M., Adamo, R. G., Lam, E., Costa, A. F., van der Pol, C. B., Salameh, J. P., Dawit, H., McInnes, M. D. F., & Bashir, M. R. (2023). Conversion Strategy for LI-RADS Category 5 Observations across Versions 2014, 2017, and 2018. Radiology, 307(4). https://doi.org/10.1148/radiol.222971
Vancouver
Goins SM, Adamo RG, Lam E, Costa AF, van der Pol CB, Salameh JP, et al. Conversion Strategy for LI-RADS Category 5 Observations across Versions 2014, 2017, and 2018. Radiology. 2023;307(4). doi:10.1148/radiol.222971
BibTeX
@article{Goins2023,
author = {Goins, Stacy M and Adamo, Robert G and Lam, Eric and Costa, Andreu F and van der Pol, Christian B and Salameh, Jean-Paul and Dawit, Haben and McInnes, Matthew D F and Bashir, Mustafa R},
title = {Conversion Strategy for LI-RADS Category 5 Observations across Versions 2014, 2017, and 2018},
journal = {Radiology},
year = {2023},
volume = {307},
number = {4},
doi = {10.1148/radiol.222971}
}
EUVIMED